Press release
CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook
- Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies – - Partnered Clinical Programs Advancing - - Multiple Updates Anticipated Across
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":" - Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies –\n - Partnered Clinical Programs Advancing - - Multiple Updates Anticipated Across Portfolio in 2020 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today provided an update on its lead programs and 2020 clinical portfolio outlook. “Our clinical pipeline today reflects the continued progress we have made in advancing our two wholly-owned lead programs, CX-072 and CX-2009, from initial clinical proof of concept into Phase 2 clinical development,” said Sean McCarthy, D. Phil., president, chief executive officer and chairman of CytomX Therapeutics. “Throughout 2019, we have also gained additional momentum in our partnered clinical programs. Bristol-Myers Squibb is advancing the anti-CTLA-4 probody, BMS-986249, into Phase 2 and the CytomX team continues Phase 1 dose escalation of CX-2029, an anti-CD71 probody drug conjugate, in partnership with AbbVie. All four of these clinical stage programs have the potential to make a meaningful difference for cancer patients and we look forward to providing updates in 2020.” PROCLAIM-CX-072 is a Phase 1/2 clinical program studying CX-072, an anti-PD-L1 Probody therapeutic in patients with solid tumors. In November 2019, the Company announced the initiation of a Simon 2 Stage Phase 2 clinical trial studying CX-072 in combination with YERVOY® (ipilimumab) in relapsed or refractory melanoma. Stage 1 of this study aims to enroll up to 40 patients. The Phase 1 expansion arm of PROCLAIM-CX-072 studying CX-072 as monotherapy in selected tumor types, has completed enrollment. Data presented at the 2019 Annual Meeting of the American Society of Clinical Oncology confirmed evidence of clinical activity in several cancer types including triple negative breast cancer, squamous cell carcinoma and cutaneous squamous cell carcinoma with an encouraging safety profile. At this time, CytomX plans to focus further clinical development within this program on combinations with CX-072, including the ongoing Phase 2 study with ipilimumab. PROCLAIM-CX-2009 is a Phase 1/2 clinical program studying CX-2009, a...